- Home
- CMMB vs CDIO Comparison
CMMB vs CDIO Comparison
Compare CMMB & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- CDIO
- Stock Information
- Founded
- CMMB 2004
- CDIO 2017
- Country
- CMMB Israel
- CDIO United States
- Employees
- CMMB N/A
- CDIO N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- CDIO Biotechnology: Commercial Physical & Biological Resarch
- Sector
- CMMB Health Care
- CDIO Health Care
- Exchange
- CMMB Nasdaq
- CDIO Nasdaq
- Market Cap
- CMMB 23.0M
- CDIO 7.0M
- IPO Year
- CMMB N/A
- CDIO N/A
- Fundamental
- Price
- CMMB $1.32
- CDIO $3.99
- Analyst Decision
- CMMB Strong Buy
- CDIO Buy
- Analyst Count
- CMMB 2
- CDIO 1
- Target Price
- CMMB $8.50
- CDIO $60.00
- AVG Volume (30 Days)
- CMMB 109.4K
- CDIO 103.1K
- Earning Date
- CMMB 05-15-2025
- CDIO 05-15-2025
- Dividend Yield
- CMMB N/A
- CDIO N/A
- EPS Growth
- CMMB N/A
- CDIO N/A
- EPS
- CMMB N/A
- CDIO N/A
- Revenue
- CMMB N/A
- CDIO $19,902.00
- Revenue This Year
- CMMB N/A
- CDIO $1,434.82
- Revenue Next Year
- CMMB N/A
- CDIO $4,661.91
- P/E Ratio
- CMMB N/A
- CDIO N/A
- Revenue Growth
- CMMB N/A
- CDIO N/A
- 52 Week Low
- CMMB $0.78
- CDIO $3.40
- 52 Week High
- CMMB $2.55
- CDIO $53.10
- Technical
- Relative Strength Index (RSI)
- CMMB 50.69
- CDIO 32.33
- Support Level
- CMMB $1.31
- CDIO $3.84
- Resistance Level
- CMMB $1.44
- CDIO $4.42
- Average True Range (ATR)
- CMMB 0.08
- CDIO 0.69
- MACD
- CMMB 0.00
- CDIO 0.04
- Stochastic Oscillator
- CMMB 54.55
- CDIO 22.96
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About CDIO Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.